TCGA-AQ-A04J-01A-02R-A034-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 27
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.470
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.430
- IL6_JAK_STAT3_SIGNALING+0.360
- WNT_BETA_CATENIN_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.340
- HEDGEHOG_SIGNALING+0.310
- KRAS_SIGNALING_UP+0.310
- MYC_TARGETS_V1+0.280
- ANGIOGENESIS+0.270
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.430
- OXIDATIVE_PHOSPHORYLATION-0.390
- ESTROGEN_RESPONSE_LATE-0.350
- ADIPOGENESIS-0.320
- PROTEIN_SECRETION-0.290
- FATTY_ACID_METABOLISM-0.250
- BILE_ACID_METABOLISM-0.170
- PEROXISOME-0.140
- XENOBIOTIC_METABOLISM-0.130
- PANCREAS_BETA_CELLS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AO-A0J4-01A-11R-A034-07 | — | E | 0.844 |
| 2 | TCGA-A2-A0SX-01A-12R-A084-07 | — | D | 0.842 |
| 3 | 7c4477a6-c744-412a-8571-bfb62f0dc714 | — | — | 0.818 |
| 4 | TCGA-BH-A18V-01A-11R-A12D-07 | — | E | 0.803 |
| 5 | TCGA-B6-A400-01A-11R-A239-07 | — | E | 0.799 |
| 6 | TCGA-A8-A08X-01A-21R-A00Z-07 | — | C | 0.797 |
| 7 | TCGA-EW-A1OW-01A-21R-A144-07 | — | E | 0.796 |
| 8 | ERR2278875 | — | — | 0.793 |
| 9 | TCGA-BH-A0BL-01A-11R-A115-07 | — | D | 0.784 |
| 10 | TCGA-A8-A08R-01A-11R-A034-07 | — | E | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |